Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX7 plus Camrelizumab and Apatinib for BCLC Stage A/B HCC
NCT06607107Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Started Feb 2024; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06607107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607107.